Mammalian target of rapamycin (mTOR) inhibitors have led to the improvement of clinical outcomes in RCC, and a strong synergy is achieved combining IGF1R and mTOR inhibitors (35). The gene discussed is IGF1R; the disease is renal cell adenocarcinoma.